Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer

The Journal of Clinical Oncology has published the final efficacy and safety results from the phase I/II ARROW trial evaluating pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer. Pralsetinib is a selective RET kinase inhibitor designed for the subset of NSCLC patients harboring RET gene fusions, which occur in approximately 1-2% of cases. The final data from this registrational study provide the mature long-term outcomes that inform clinical decision-making for this molecularly defined patient population. These results consolidate the evidence supporting targeted RET inhibition as an effective treatment strategy in this genomically selected group of lung cancer patients.